Sonnet BioTherapeutics (SONN) reported Tuesday that its stockholders have approved, among other things, the proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC.

Shares of the company slumped 55% following an increase in intraday trading volume to over 7 million from a daily average of roughly 958,000.

Janux Therapeutics (JANX) shares plunged 51% after the company reported late Monday interim data from its phase 1 trial of the JANX007 drug candidate to treat metastatic castration-resistant prostate cancer.

More than 11.5 million shares of the company traded intraday compared with a daily average of about 1 million.

Health In Tech (HIT) said Tuesday its executive management team, vice presidents, and the board have voluntarily agreed to extend the lock-up restrictions on all shares they hold for an additional six months beyond the original 12-month lock-up in connection with its initial public offering last year.

Shares of the company dropped 21% as intraday trading volume rose to more than 1.1 million from a daily average of roughly 396,000.

Price: 1.38, Change: -1.72, Percent Change: -55.48